Mo1703 Incidence of Selected Adverse Events (AES) in Inflammatory Bowel Disease (IBD) Patients With and Without Exposure to Anti-Tumor Necrosis Factor Alpha (Anti-TNFa) Therapy

Differences in the incidence of flares o

Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti–tumor necrosis factor α agents

✍ Braun, J. ;Baraliakos, X. ;Listing, J. ;Davis, J. ;van der Heijde, D. ;Haibel, H 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Abstract ## Objective Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are clinically and pathologically linked. Anti–tumor necrosis factor (anti‐TNF) agents are efficacious in treating AS, but not all are equally effective in treating IBD (Crohn's disease [CD] and ulcerative co